The Power of CAR T
Backed by Pivotal data
with 2-year post hoc analysis

// Innovative Therapy1

The first CAR T therapy for certain types of relapsed or refractory large B-cell lymphoma.

Manufacturing Matters

// Rapid and Reliable Manufacturing

In the ZUMA-1 (study design) pivotal trial, Kite demonstrated a median turnaround time of 17 days and 99% manufacturing success rate.1